Christopher Park, MD, PhD

Principal Investigator
Christopher.Park@nyulangone.org

Iryna Berezniuk, PhD

Senior Research Scientist
Iryna.Berezniuk@nyulangone.org

Previously in our lab it was discovered that AML leukemic stem cells (LSCs) highly express a cell surface protein CD99. This marker makes malignant cells more quiescent, low-translating, and it promotes leukemia engraftment and propagation in vivo. I isolate leukemic cells from primary AML patient specimens based on the levels of CD99 expression and investigate pathways that regulate translation.

Nainita Roy Bhowmick, PhD

Postdoctoral Fellow
Nainita.Bhowmick@nyulangone.org

Our lab has shown GPCRs to be independent prognostic predictors in acute myeloid leukemia. I am investigating the importance of isoform switching of GPCRs, in regulating stem cell renewal, blast proliferation, and differentiation, and how that affects AML pathogenesis.

Mohamed A. E. Ali, MD, PhD

Postdoctoral Fellow
Mohamed.Ali@nyulangone.org

It has been reported that hematopoietic stem cells (HSCs) require highly regulated global protein translation and that stem cells have the lowest rates of translation compared to progenitors and mature cells. My work is focused on investigating the translational regulation of leukemia initiating cells (LICs), and dissecting leukemia blast heterogeneity, in T-cell acute lymphoblastic leukemia (T-ALL).

Sohini Chakraborty, PhD

Postdoctoral Fellow
sohini.chakraborty@nyulangone.org

I am working on investigating potential resistance mediators to chemotherapy in acute myeloid leukemia (AML) and elucidating the molecular mechanisms of their activity in chemo-resistant leukemic cells. I am also investigating various ‘omics’ data to analyze the cellular, and functional heterogeneity in normal, and malignant stem cells in the hematopoietic system.

Di Zhan, PhD

Postdoctoral Fellow
Di.Zhan@nyulangone.org

Malignant stem cells must be eradicated to cure disease. Antibody-drug conjugates (ADC) are capable of targeting malignant stem cells while sparing healthy cell populations. I am currently investigating the molecular mechanisms, as well as potential clinical applications of specific CD117-drug conjugate to eliminate malignant stem cells in myelodysplastic syndrome(MDS).

Hidenori Kasahara, MD, PhD

Postdoctoral Fellow
Hidenori.Kasahara@nyulangone.org

Recent discoveries have emphasized on the importance of a tightly regulated cross-talk between transcription and translation, in the maintenance of cellular stemness. My research work focuses on investigating this cross-talk, in the context of malignant stem cells, particularly in acute myeloid leukemia (AML), using primary patient samples.

Guangjie Zhao, MD

Graduate Student Intern
Guangjie.Zhao@nyulangone.org

I am investigating drug resistance in leukemia and myelodysplastic syndromes.

Ming Yu, MD

Research Associate
Ming.Yu@nyulangone.org

Amyloidosis is a rare plasma cell disorder, where over-secreted light chains form beta-pleated sheets and deposit in the vital organs of the body. I’m working to identify genes which affect the proliferation and antibody secretion in these aberrant plasma cells in Amyloidosis.

Thomas Paloschi, MD

Research Associate
Thomas.Paloschi@nyulangone.org

There is strong evidence that the hematopoietic system plays a major role in aging and longevity. My research efforts are directed towards elucidating the role of hematopoietic stem cells and their regulating effects on aging. I am interested in the potential implementation of this research in combating age related diseases.

Jiangrui Guo, MD

Research Associate
Jiangrui.Guo@nyulangone.org

Gene mutations and translocations play key roles in tumor occurrence and development. I am studying the role of newly identified fusion genes in tumors.

Afreen Karimkhan, MD, DipRCPath

Research Associate
karimkhan.afreen@nyulangone.org

Right from my Pathology residency days in India, I have been committed to research on hematological malignancies. Identification of newer antigen on hematopoietic stem cells and elucidating molecular mechanisms that regulate the transition to malignancy is challenging and can offer pioneering ways to manage such malignancies . This inspires me to contribute to this research.

Charlotte Agliata

Volunteer
Charlotte.Agliata@nyulangone.org

David Zhou

Volunteer
David.Zhou@nyulangone.org

NYU undergrad